Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Anecdotal responses, some lasting for months, can be seen with aggressive antibiotic treatment of Staphylococcus aureus, with corresponding decreased expression of interleukin-2 receptors, STAT signaling, and T-cell proliferation.[1][Level of evidence C3]
Sources: 1 · Level of evidence C3
These types of treatments produce remissions, but long-term remissions are uncommon. Treatment is considered palliative for most patients, although major symptomatic improvement is regularly achieved. Survival of more than 8 years is common for patients with early stages of disease. All patients with cutaneous T-cell lymphomas are candidates for clinical trials evaluating new approaches to treatment.
| Stage (TNM Definitions) | Treatment Options |
|---|---|
| Stage I and Stage II Mycosis Fungoides | Photodynamic therapy |
| Radiation therapy | |
| Biological therapy | |
| Chemotherapy | |
| Other drug therapy | |
| Targeted therapy | |
| Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome | Photodynamic therapy |
| Radiation therapy | |
| Biological therapy | |
| Chemotherapy | |
| Other drug therapy | |
| Targeted therapy | |
| Checkpoint inhibitors | |
| Recurrent Mycosis Fungoides and Sézary Syndrome | Radiation therapy |
| Photodynamic therapy | |
| Chemotherapy | |
| Other drug therapy | |
| Biological therapy | |
| Allogeneic stem cell transplant | |
| Targeted therapy | |
| Primary Cutaneous Anaplastic Large Cell Lymphoma | Radiation therapy |
| Targeted therapy | |
| Chemotherapy | |
| Subcutaneous Panniculitis-Like T-Cell Lymphoma | Immunosuppression |
| Chemotherapy | |
| Targeted therapy | |
| Allogeneic stem cell transplant | |
| Primary Cutaneous Gamma Delta T-Cell Lymphoma | Chemotherapy |
| Allogeneic stem cell transplant | |
| Primary Cutaneous Aggressive Epidermotropic CD8-Positive T-Cell Lymphoma | Chemotherapy |
| Allogeneic stem cell transplant |
Sources: TNM Definitions · Photodynamic therapy · Radiation therapy · Biological therapy · Chemotherapy · Other drug therapy · Targeted therapy · Photodynamic therapy · Radiation therapy · Biological therapy · Chemotherapy · Other drug therapy · Targeted therapy · Checkpoint inhibitors · Radiation therapy · Photodynamic therapy · Chemotherapy · Other drug therapy · Biological therapy · Allogeneic stem cell transplant · Targeted therapy
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Several forms of treatment can completely resolve skin lesions at stages I and II, so the choice of therapy depends on local expertise and the facilities available. With therapy, the survival of patients with stage IA disease can be expected to be the same as for age- and sex-matched controls.[1-3]
There is no curative therapy and no clear difference in overall survival (OS) among the treatment options for patients with stage I and stage II mycosis fungoides.
A randomized study of 103 patients compared combined total-skin electron-beam radiation (TSEB) plus combination chemotherapy with sequential topical therapies.[4] In the latter group, combination chemotherapy was reserved for patients with symptomatic extracutaneous disease or disease that was refractory to topical therapies. Patients with any disease stage were eligible. Although the complete response rate was higher with combined therapy, toxic effects were considerably greater, and no difference was seen in disease-free survival (DFS) or OS between the two groups.[4][Level of evidence A1]
Sources: 4 · 4 · Level of evidence A1
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Treatment options for stages I and II mycosis fungoides include the following:[5]
Sources: 5
Photodynamic therapy.
Sources: Photodynamic therapy
Radiation therapy.
Sources: Radiation therapy
Biological therapy.
Sources: Biological therapy
Chemotherapy.
Sources: Chemotherapy
Other drug therapy.
Sources: Other drug therapy
Targeted therapy.
Sources: Targeted therapy
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Psoralen and ultraviolet A (PUVA) radiation therapy.[6-11]
Therapeutic trials with PUVA have shown an 80% to 90% complete remission rate in patients, with those in early cutaneous stages achieving the best responses. PUVA may be used in conjunction with systemic treatment.[10] Continued maintenance therapy with PUVA at more protracted intervals is generally required to prolong remission duration.[6-8,10] PUVA combined with interferon alfa-2a is associated with a high response rate.[9,10]
Narrowband ultraviolet B radiation.[12,13]
Single-arm and retrospective comparisons confirm the efficacy of narrowband ultraviolet B with 80% to 90% complete remission rates, especially for patients with early cutaneous stages.[12,13]
A Cochrane systematic review and meta-analysis compared PUVA with narrowband ultraviolet B radiation in 778 patients with early-stage mycosis fungoides (stage IA, IB, and IIA). Significantly higher complete responses were seen in patients treated with PUVA (73.8% vs. 62.2%; hazard ratio, 1.68; 95% confidence interval [CI], 1.02–2.76; P = .04). There were no significant differences in adverse effects.[11][Level of evidence B3]
Sources: 11 · Level of evidence B3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
TSEB.[14-19]
Electron-beam radiation therapy of appropriate energies will penetrate only to the dermis, and thus, the skin alone can be treated without systemic effects. This therapy requires a radiation therapy facility with physics support and considerable technical expertise to deliver precise dosimetry. TSEB can result in short- and long-term cutaneous toxic effects and is not widely available.
This therapy can provide excellent palliation, with complete response rates as high as 80%, and may be combined with systemic treatment. Based on the long-term survival of these early-stage patients, electron-beam radiation therapy is sometimes used with curative intent.[14-18] Long-term DFS can be achieved in patients with unilesional mycosis fungoides treated with local radiation therapy.[19]
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Interferon alfa or interferon gamma alone or in combination with topical therapy.[22,23][Level of evidence C3]
Sources: 22 · 23 · Level of evidence C3
Interferon alfa or interferon gamma alone or in combination with topical therapy.[22,23][Level of evidence C3]
A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the time-to-next-treatment (TTNT) between patients who received interferon alfa and conventional chemotherapy. Interferon alfa provided a longer TTNT of 8.7 months (95% CI, 6.0–18.0) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1) (P < .00001).[23][Level of evidence C3]
Sources: 23 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Chemotherapeutic agents generally demonstrate short durations of response. In a retrospective review of 198 patients with advanced-stage disease, the median TTNT was 4 months.[23] However, these comparisons may be confounded by the order in which the agents were introduced.
Sources: 23
Topical chemotherapy with mechlorethamine.[14,24,25]
This form of treatment may be used palliatively or to supplement therapeutic approaches directed against nodal or visceral disease. Topical application of mechlorethamine has produced regression of cutaneous lesions, with particular efficacy in early stages of disease. The overall complete remission rate is related to skin stage; 50% to 80% of TNM classification T1 patients, 25% to 75% of T2 patients, as many as 50% of T3 patients, and 20% to 40% of T4 patients have complete responses. The overall complete remission rate in 243 patients was 64% and was related to stage; as many as 35% of stage IV patients had complete responses. Treatments are usually continued for 2 to 3 years. Continuous 5-year DFS may be possible in as many as 33% of T1 patients.[14,24,25]
Oral methotrexate (NCT00425555).[26]
Sources: NCT00425555 · 26
Fludarabine, cladribine, and pentostatin are active agents for mycosis fungoides.[30-33]
Single-agent chemotherapy or combination systemic chemotherapy (chlorambucil plus prednisone, mechlorethamine, cyclophosphamide, methotrexate) is often combined with treatment directed at the skin.[4,23,34,35]
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Symptomatic management with topical corticosteroids. Low potency steroids can be used on the face with safety and efficacy.[38]
Sources: 38
Bexarotene, an oral or topical retinoid (NCT00255801).[39,40]
Sources: NCT00255801 · 39 · 40
Lenalidomide.[41]
Sources: 41
Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[23,42-44][Level of evidence C3]
Sources: 23 · 42 · 44 · Level of evidence C3
Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[23,42-44][Level of evidence C3]
A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; P = .01).[23][Level of evidence C3]
Sources: 23 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Brentuximab vedotin.[45,46]
Two phase II trials of 58 patients with variable CD30 expression showed a 50% to 70% response rate with 50% of patients still in remission after 1 year.[45,46][Level of evidence C3]
Sources: 45 · 46 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Mycosis Fungoides
There is no curative therapy and no clear difference in overall survival (OS) among the treatment options for patients with stage III and stage IV disease.
The use of single alkylating agents has produced objective responses in 60% of patients, with a duration of less than 6 months. One of the alkylating agents (e.g., mechlorethamine, cyclophosphamide, or chlorambucil) or the antimetabolite methotrexate is the most frequently used. Single agents have not cured any patients, and insufficient data exist to determine whether these agents prolong survival. Combination chemotherapy is not definitely superior to single agents. Even in patients with stage IV disease, treatments directed at the skin may provide significant palliation.
A randomized study of 103 patients compared combined total-skin electron-beam radiation (TSEB) plus combination chemotherapy with conservation therapy consisting of sequential topical therapies.[1] In the latter group, combination chemotherapy was reserved for patients with symptomatic extracutaneous disease or disease that was refractory to topical therapies. Patients with any disease stage were eligible. Although the complete response rate was higher with combined therapy, toxic effects were considerably greater, and no difference was seen in disease-free survival (DFS) or OS between the two groups.[1][Level of evidence A1]
Sources: 1 · 1 · Level of evidence A1
Sézary Syndrome
Sézary syndrome is a rare leukemic variant of cutaneous T-cell lymphoma. It is characterized by erythroderma, circulating Sézary cells with cerebriform nuclei, lymphadenopathy, and pruritus.[2] This condition typically progresses rapidly, with only a short duration of response to most therapies. A retrospective review of 176 patients with Sézary syndrome identified the following poor prognostic factors:[3]
High lactate dehydrogenase.
Previous diagnosis of mycosis fungoides.
Presence of T-cell receptor gene rearrangements in skin, blood, or both.
Remissions attained by using extracorporeal photophoresis, interferon alfa, or retinoids may be followed by allogeneic stem cell transplant. In an anecdotal series of 16 patients with Sézary syndrome after allogeneic transplant, 9 were in complete remission after 4 years.[4]
Sources: 4
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Treatment options for stages III and IV mycosis fungoides and Sézary syndrome include the following (note that in this clinical setting, the skin is easily injured; any of the topical therapies must be administered with extreme caution):[2,5]
Photodynamic therapy.
Sources: Photodynamic therapy
Radiation therapy.
Sources: Radiation therapy
Biological therapy.
Sources: Biological therapy
Chemotherapy.
Sources: Chemotherapy
Other drug therapy.
Sources: Other drug therapy
Targeted therapy.
Sources: Targeted therapy
Checkpoint inhibitors.
Sources: Checkpoint inhibitors
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Psoralen and ultraviolet A (PUVA) radiation therapy.[6-11]
Therapeutic trials with PUVA have shown an 80% to 90% complete remission rate in patients, with those in early cutaneous stages achieving the best responses. PUVA may be used in conjunction with systemic treatment.[10] Continued maintenance therapy with PUVA at more protracted intervals is generally required to prolong remission duration.[6-8,10] PUVA combined with interferon alfa-2a is associated with a high response rate.[9,10]
Narrowband ultraviolet B radiation.[12,13]
Single-arm and retrospective comparisons confirm the efficacy of narrowband ultraviolet B with 80% to 90% complete remission rates, especially for patients with early cutaneous stages.[12,13]
A Cochrane systematic review and meta-analysis compared PUVA with narrowband ultraviolet B radiation in 778 patients with early-stage mycosis fungoides (stage IA, IB, and IIA). Significantly higher complete responses were seen in patients treated with PUVA (73.8% vs. 62.2%; hazard ratio, 1.68; 95% confidence interval [CI], 1.02–2.76; P = .04). There were no significant differences in adverse effects.[11][Level of evidence B3]
Sources: 11 · Level of evidence B3
Extracorporeal photophoresis (ECP) alone [14-17] or in combination with TSEB.[18] ECP is particularly applicable for Sézary syndrome and erythrodermic mycosis fungoides.[17]
Extracorporeal photophoresis (ECP) alone [14-17] or in combination with TSEB.[18] ECP is particularly applicable for Sézary syndrome and erythrodermic mycosis fungoides.[17]
In a retrospective analysis of 65 patients, with a median follow-up of 48 months, use of ECP in the first to third line of treatment yielded a longer median time-to-next treatment (TTNT) than other systemic options (P < .03).[17][Level of evidence C3]
Sources: 17 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
TSEB.[19-24]
Electron-beam radiation therapy of appropriate energies will penetrate only to the dermis, and thus, the skin alone can be treated without systemic effects. This therapy requires a radiation therapy facility with physics support and considerable technical expertise to deliver precise dosimetry. TSEB can result in short- and long-term cutaneous toxic effects and is not widely available.
This therapy can provide excellent palliation, with complete response rates as high as 80%, and may be combined with systemic treatment. Based on the long-term survival of these early-stage patients, electron-beam radiation therapy is sometimes used with curative intent.[19-23] Long-term DFS can be achieved in patients with unilesional mycosis fungoides treated with local radiation therapy.[24]
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Interferon alfa alone or in combination with other agents, such as topical therapy.[27,28]
Interferon alfa alone or in combination with other agents, such as topical therapy.[27,28]
A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between patients who received interferon alfa and conventional chemotherapy. Interferon alfa provided a longer TTNT of 8.7 months (95% CI, 6.0–18.0) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1) (P < .00001).[29][Level of evidence C3]
Sources: 29 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Chemotherapeutic agents generally demonstrate short durations of response. In a retrospective review of 198 patients with advanced-stage disease, the median TTNT was 4 months.[29] However, these comparisons may be confounded by the order in which the agents were introduced.
Sources: 29
Oral methotrexate (NCT00425555).[30]
Sources: NCT00425555 · 30
Fludarabine, cladribine, and pentostatin are active agents for mycosis fungoides and Sézary syndrome.[27,29,31-33]
Single-agent chemotherapy or combination systemic chemotherapy (chlorambucil plus prednisone, mechlorethamine, cyclophosphamide, methotrexate) often combined with treatment directed at the skin.[1,29,34,35]
Topical chemotherapy with mechlorethamine.[36,37]
This form of treatment may be used palliatively or to supplement therapeutic approaches directed against nodal or visceral disease. Topical application of mechlorethamine has produced regression of cutaneous lesions, with particular efficacy in early stages of disease. The overall complete remission rate is related to skin stage; 50% to 80% of TNM classification T1 patients, 25% to 75% of T2 patients, as many as 50% of T3 patients, and 20% to 40% of T4 patients have complete responses. The overall complete remission rate in 243 patients was 64% and was related to stage; as many as 35% of stage IV patients had complete responses. Treatments are usually continued for 2 to 3 years. Continuous 5-year DFS may be possible in as many as 33% of T1 patients.[19,36,37]
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Symptomatic management with topical corticosteroids. Low potency steroids can be used on the face with safety and efficacy.[43]
Sources: 43
Lenalidomide.[44]
Sources: 44
Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[2,47-49]
Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[2,47-49]
A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; P = .01).[29][Level of evidence C3]
Sources: 29 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Brentuximab vedotin.[50,51]
Two phase II trials of 58 patients with variable CD30 expression showed a 50% to 70% response rate with 50% of patients still in remission after 1 year.[50,51][Level of evidence C3]
Sources: 50 · 51 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Pembrolizumab.[52]
Sources: 52
Pembrolizumab.[52]
Anecdotal responses have been seen in patients with advanced relapsed or refractory mycosis fungoides. In a single-arm, multicenter, phase II trial of 24 patients treated with pembrolizumab, the overall response rate was 38%.[52][Level of evidence C3]
Sources: 52 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
The treatment of patients with relapsed mycosis fungoides and Sézary syndrome involves the joint decisions of a dermatologist, medical oncologist, and radiation oncologist. It may be possible to re-treat localized areas of relapse in the skin with additional electron-beam radiation therapy or to repeat total-skin electron-beam radiation therapy (TSEB).[1] Photon radiation to bulky skin or nodal masses may prove beneficial. If these options are not possible, then continued topical treatment with other modalities, such as mechlorethamine or psoralen and ultraviolet A radiation (PUVA) may be warranted to relieve cutaneous symptoms.
Sources: 1
Patients should consider clinical trials as a therapeutic option.
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Treatment options under clinical evaluation for recurrent mycosis fungoides and Sézary syndrome include the following:[2,3]
Radiation therapy.
Sources: Radiation therapy
Photodynamic therapy.
Sources: Photodynamic therapy
Chemotherapy.
Sources: Chemotherapy
Other drug therapy.
Sources: Other drug therapy
Biological therapy.
Sources: Biological therapy
Allogeneic stem cell transplant.
Sources: Allogeneic stem cell transplant
Targeted therapy.
Sources: Targeted therapy
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Additional electron-beam radiation therapy or a repeat of TSEB.
Additional electron-beam radiation therapy or a repeat of TSEB.
Electron-beam radiation therapy of appropriate energies will penetrate only to the dermis, and thus, the skin alone can be treated without systemic effects. This therapy requires a radiation therapy facility with physics support and considerable technical expertise to deliver precise dosimetry. TSEB can result in short- and long-term cutaneous toxic effects and is not widely available.
This therapy can provide excellent palliation, with complete response rates as high as 80%, and may be combined with systemic treatment. Based on the long-term survival of these early-stage patients, electron-beam radiation therapy is sometimes used with curative intent.[4-8] Long-term disease-free survival (DFS) can be achieved in patients with unilesional mycosis fungoides treated with local radiation therapy.[9]
Photon radiation to bulky skin or nodal masses.[10]
Sources: 10
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
PUVA radiation therapy.[11-16]
Therapeutic trials with PUVA have shown an 80% to 90% complete remission rate in patients, with those in early cutaneous stages achieving the best responses. PUVA may be used in conjunction with systemic treatment.[15] Continued maintenance therapy with PUVA at more protracted intervals is generally required to prolong remission duration.[11-13,15] PUVA combined with interferon alfa-2a is associated with a high response rate.[14,15]
Narrowband ultraviolet B radiation.[17,18]
Single-arm and retrospective comparisons confirm the efficacy of narrowband ultraviolet B with 80% to 90% complete remission rates, especially for patients with early cutaneous stages.[17,18]
A Cochrane systematic review and meta-analysis compared PUVA with narrowband ultraviolet B radiation in 778 patients with early-stage mycosis fungoides (stage IA, IB, and IIA). Significantly higher complete response rates were seen in patients treated with PUVA (73.8% vs. 62.2%; hazard ratio [HR], 1.68; 95% confidence interval [CI], 1.02–2.76; P = .04). There were no significant differences in adverse effects.[16][Level of evidence B3]
Sources: 16 · Level of evidence B3
Extracorporeal photophoresis (ECP) has produced tumor regression in patients who are resistant to other therapies.[19,20]
Extracorporeal photophoresis (ECP) has produced tumor regression in patients who are resistant to other therapies.[19,20]
In a retrospective analysis of 65 patients, with a median follow-up of 48 months, use of ECP in the first to third line of treatment yielded a longer median time-to-next treatment (TTNT) than other systemic options (P < .03).[21][Level of evidence C3]
Sources: 21 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Topical treatment with mechlorethamine or PUVA.
Topical treatment with mechlorethamine or PUVA.
This form of treatment may be used palliatively or to supplement therapeutic approaches directed against nodal or visceral disease. Topical application of mechlorethamine has produced regression of cutaneous lesions, with particular efficacy in early stages of disease. The overall complete remission rate is related to skin stage; 50% to 80% of TNM classification T1 patients, 25% to 75% of T2 patients, as many as 50% of T3 patients, and 20% to 40% of T4 patients have complete responses. The overall complete remission rate in 243 patients was 64% and was related to stage; as many as 35% of stage IV patients had complete responses. Treatments are usually continued for 2 to 3 years. Continuous 5-year DFS may be possible in as many as 33% of T1 patients.[4,22,23]
Pralatrexate (folate analogue).[24,25]
Chemotherapeutic agents generally yield short durations of response. In a retrospective review of 198 patients with advanced-stage disease, the median TTNT was 4 months.[26]
Sources: 26
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Symptomatic management with topical corticosteroids.
Lenalidomide.[35]
Sources: 35
Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[36-38]
A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; P = .01).[26][Level of evidence C3]
Sources: 26 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Interferon alfa alone or in combination with other agents, such as topical therapy.[39,40]
Interferon alfa alone or in combination with other agents, such as topical therapy.[39,40]
A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between patients who received interferon alfa and conventional chemotherapy. Interferon alfa provided a longer TTNT of 8.7 months (95% CI, 6.0–18.0) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1) (P < .00001).[26][Level of evidence C3]
Sources: 26 · Level of evidence C3
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Brentuximab vedotin.[46,47]
Two phase II trials of 58 patients with variable CD30 expression showed a 50% to 70% response rate with 50% of patients still in remission after 1 year.[46,47][Level of evidence C3]
Sources: 46 · 47 · Level of evidence C3
Mogamulizumab.[48]Mogamulizumab is often avoided in patients scheduled to undergo allogeneic SCT, based on data from a Japanese study that showed an increased risk of severe graft-versus-host disease (GVHD) in patients treated with mogamulizumab beforehand.[49] The relevance of these findings in other countries and the impact of different GVHD prophylaxis regimens in these patients remains to be determined.
Mogamulizumab.[48]Mogamulizumab is often avoided in patients scheduled to undergo allogeneic SCT, based on data from a Japanese study that showed an increased risk of severe graft-versus-host disease (GVHD) in patients treated with mogamulizumab beforehand.[49] The relevance of these findings in other countries and the impact of different GVHD prophylaxis regimens in these patients remains to be determined.
In a prospective randomized trial, 372 previously treated patients received either mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, or the HDACi vorinostat.
Mogamulizumab.[48]Mogamulizumab is often avoided in patients scheduled to undergo allogeneic SCT, based on data from a Japanese study that showed an increased risk of severe graft-versus-host disease (GVHD) in patients treated with mogamulizumab beforehand.[49] The relevance of these findings in other countries and the impact of different GVHD prophylaxis regimens in these patients remains to be determined. › In a prospective randomized trial, 372 previously treated patients received either mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, or the HDACi vorinostat.
With a median follow-up of 17 months, the median progression-free survival was 7.7 months for patients who received mogamulizumab and 3.1 months for patients who received vorinostat (HR, 0.53; 95% CI, 0.41−0.69; P < .0001).[48][Level of evidence B1]
Sources: 48 · Level of evidence B1
Mogamulizumab appeared to be especially effective in patients with blood involvement, such as those with Sézary syndrome.
This preliminary study was not designed to detect differences in OS.
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Primary cutaneous anaplastic large cell lymphoma presents in the skin only with no preexisting lymphoproliferative disease and no extracutaneous sites of involvement.[1-3] Patients with this type of lymphoma have disease ranging from clinically benign lymphomatoid papulosis, marked by localized nodules that may regress spontaneously, to progressive and systemic illness requiring aggressive doxorubicin-based combination chemotherapy. This spectrum has been called the primary cutaneous CD30-positive T-cell lymphoproliferative disorder.
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is localized to subcutaneous tissue and can be associated with hemophagocytic lymphohistiocytosis (HLH).[1-4] Anecdotal reports suggest that the presence or absence of HLH is an important prognostic indicator.[5] Patients with SPTCL have cells that express alpha-beta phenotype.
Patients with gamma-delta phenotype have a more aggressive clinical course that is instead classified as primary cutaneous gamma-delta T-cell lymphoma.[6-8] For more information, see Peripheral T-Cell Non-Hodgkin Lymphoma Treatment.
Sources: 6 · 8 · Peripheral T-Cell Non-Hodgkin Lymphoma Treatment
The management of SPTCL depends on the clinical presentation—including the severity of symptoms, cytopenias, and the presence or absence of HLH—and the apparent disease trajectory and aggressiveness. Indolent or smoldering forms of SPTCL are often treated with immunosuppression, including oral methotrexate [9] or cyclosporine.[10] In contrast, aggressive forms are frequently treated with combination chemotherapy such as CHO(E)P (cyclophosphamide, doxorubicin, vincristine, and prednisone with or without etoposide) with variable responses per anecdotal reports.[11] The JAK2 inhibitor ruxolitinib has also been used in SPTCL with associated HLH, including anecdotal reports of responses in patients with disease that did not respond to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy.[12] In cases of particularly aggressive or relapsed disease, consolidation with allogeneic stem cell transplant has also been used.[13,14]
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Primary cutaneous gamma-delta T-cell lymphoma (PCGDTCL) is a rare and extremely aggressive form of cutaneous T-cell lymphoma with a poor prognosis. These patients may manifest involvement of the epidermis, dermis, subcutaneous region, or mucosa with or without ulceration. PCGDTCL is treated similarly to the most aggressive peripheral T-cell lymphomas, with CHO(E)P (cyclophosphamide doxorubicin, vincristine, and prednisone with or without etoposide).[1-5] For patients achieving remission, there are reports of prolonged survival following consolidation with allogeneic stem cell transplant.[6]
Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 19, 2025. Captured 2026-09-09.
Primary cutaneous aggressive epidermotropic CD8-positive T-cell lymphoma is another rare and especially aggressive form of cutaneous T-cell lymphoma. Patients typically present with ulcerative plaques or tumors, and mucosal involvement is common. Neoplastic cells are characterized by expression of CD8 and a cytotoxic phenotype.[1] Multimodal chemotherapy, such as CHO(E)P (cyclophosphamide, doxorubicin, vincristine, and prednisone with or without etoposide), is often used. Outcomes are generally poor, and prolonged remissions are extremely uncommon in the absence of allogeneic stem cell transplant.[2]
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
The prognosis and treatment options depend on the following:
Sources: prognosis
The stage of the cancer.
Sources: stage
The type of lesion (patches, plaques, or tumors).
The patient's age and sex.
Mycosis fungoides and Sézary syndrome are hard to cure. Treatment is usually palliative, to relieve symptoms and improve the quality of life. Patients with earlystage disease may live many years.
Sources: cure · palliative · quality of life
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Mycosis fungoides and Sézary syndrome may come back in the skin or in other parts of the body, such as the spleen or liver.
Sources: Sézary syndrome · spleen
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
There are different types of treatment for patients with mycosis fungoides and cancer.
Seven types of standard treatment are used:
Seven types of standard treatment are used:
Photodynamic therapy
Radiation therapy
Chemotherapy
Other drug therapy
Immunotherapy
Targeted therapy
High-dose chemotherapy and radiation therapy with stem cell transplant
New types of treatment are being tested in clinical trials.
New types of treatment are being tested in clinical trials.
Immune checkpoint inhibitor therapy
Treatment for mycosis fungoides and Sézary syndrome may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up tests may be needed.
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Different types of treatment are available for patients with mycosis fungoides and . Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: mycosis fungoides · standard · clinical trials · research study · cancer
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Photodynamic therapy is a cancer treatment that uses a drug and a certain type of laser light to kill cancer cells. A drug that is not active until it is exposed to light is injected into a vein. The drug collects more in cancer cells than in normal cells. For skin cancer, laser light is shined onto the skin and the drug becomes active and kills the cancer cells. Photodynamic therapy causes little damage to healthy tissue. Patients undergoing photodynamic therapy will need to limit the amount of time spent in sunlight. There are different types of photodynamic therapy:
Sources: Photodynamic therapy · drug · laser · cells · injected · vein · skin cancer · tissue
In psoralen and ultraviolet A (PUVA) therapy, the patient receives a drug called psoralen and then ultraviolet A radiation is directed to the skin.
Sources: psoralen and ultraviolet A (PUVA) therapy · psoralen · ultraviolet A radiation
In extracorporeal photopheresis (ECP), the patient is given drugs and then some blood cells are taken from the body, put under a special ultraviolet A light, and put back into the body. ECP may be used alone or combined with total skin electron beam (TSEB) radiation therapy.
Sources: extracorporeal photopheresis · blood · ultraviolet A light · total skin electron beam (TSEB) radiation therapy
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Sometimes, total skin electron beam (TSEB) radiation therapy is used to treat mycosis fungoides and Sézary syndrome. This is a type of external radiation treatment in which a radiation therapy machine aims electrons (tiny, invisible particles) at the skin covering the whole body . External radiation therapy may also be used as palliative therapy to relieve symptoms and improve quality of life.
Sources: Radiation therapy · x-rays · radiation · External radiation therapy · electrons · palliative therapy · symptoms · quality of life
Ultraviolet A (UVA) radiation therapy or ultraviolet B (UVB) radiation therapy may be given using a special lamp or laser that directs radiation at the skin.
Sources: Ultraviolet A (UVA) radiation therapy · ultraviolet B (UVB) radiation therapy
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). Sometimes the chemotherapy is topical (put on the skin in a cream, lotion, or ointment).
Sources: Chemotherapy · systemic chemotherapy · ointment
See Drugs Approved for Non-Hodgkin Lymphoma for more information. (Mycosis fungoides and Sézary syndrome are types of non-Hodgkin lymphoma.)
Sources: Drugs Approved for Non-Hodgkin Lymphoma · non-Hodgkin lymphoma
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Topical corticosteroids are used to relieve red, swollen, and inflamed skin. They are a type of steroid. Topical corticosteroids may be in a cream, lotion, or ointment.
Sources: corticosteroids · inflamed · steroid
Retinoids, such as bexarotene, are drugs related to vitamin A that can slow the growth of certain types of cancer cells. The retinoids may be taken by mouth or put on the skin.
Sources: Retinoids · bexarotene · vitamin A
Lenalidomide is a drug that helps the immune system kill abnormal blood cells or cancer cells and may prevent the growth of new blood vessels that tumors need to grow.
Sources: Lenalidomide · immune system · abnormal · blood vessels
Vorinostat and romidepsin are two of the histone deacetylase (HDAC) inhibitors used to treat mycosis fungoides and Sézary syndrome. HDAC inhibitors cause a chemical change that stops tumor cells from dividing.
Sources: Vorinostat · romidepsin · histone deacetylase (HDAC) inhibitors
See Drugs Approved for Non-Hodgkin Lymphoma for more information. (Mycosis fungoides and Sézary syndrome are types of non-Hodgkin lymphoma.)
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer. This cancer treatment is a type of biologic therapy.
Sources: Immunotherapy · immune system · biologic therapy
Interferon: This treatment interferes with the division of mycosis fungoides and Sézary cells and can slow tumor growth.
Sources: Interferon · tumor
See Drugs Approved for Non-Hodgkin Lymphoma for more information. (Mycosis fungoides and Sézary syndrome are types of non-Hodgkin lymphoma.)
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do.
Sources: Targeted therapy
Monoclonal antibodies: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.Types of monoclonal antibodies include:
Sources: Monoclonal antibodies · proteins · antibodies · infusion · toxins · radioactive
Monoclonal antibodies: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.Types of monoclonal antibodies include:
Brentuximab vedotin, which contains a monoclonal antibody that binds to a protein, called CD30, found on some types of lymphoma cells. It also contains an anticancer drug that may help kill cancer cells.
Sources: Brentuximab vedotin · monoclonal antibody
Mogamulizumab, which contains a monoclonal antibody that binds to a protein, called CCR4, found on some types of lymphoma cells. It may block this protein and help the immune system kill cancer cells. It is used to treat mycosis fungoides and Sézary syndrome that came back or did not get better after treatment with at least one systemic therapy.
Sources: Mogamulizumab · protein · lymphoma · systemic therapy
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
High doses of chemotherapy and sometimes radiation therapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy and radiation therapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
Sources: doses · Stem cell transplant · Stem cells · bone marrow · donor · infusion
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Immune checkpoint inhibitor therapy: Immune checkpoint inhibitors block proteins called checkpoints that are made by some types of immune system cells, such as T cells, and some cancer cells. These checkpoints help keep immune responses from being too strong and sometimes can keep T cells from killing cancer cells. When these checkpoints are blocked, T cells can kill cancer cells better.
Sources: Immune checkpoint inhibitor · therapy · proteins · T cells · immune responses
PD-1 and PD-L1 inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body’s immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells. Pembrolizumab is a type of PD-1 inhibitor.
Sources: PD-1 · PD-L1 · Pembrolizumab
Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed stage I and stage II mycosis fungoides may include the following:
Psoralen and ultraviolet A (PUVA) radiation therapy.
Sources: Psoralen and ultraviolet A (PUVA) radiation therapy
Ultraviolet B radiation therapy.
Sources: Ultraviolet B radiation · therapy
Radiation therapy with total skin electron beam radiation therapy. In some cases, radiation therapy is given to skin lesions, as palliative therapy to reduce tumor size to relieve symptoms and improve quality of life.
Sources: Radiation therapy · total skin electron beam radiation therapy · lesions · palliative therapy · tumor · symptoms · quality of life
Immunotherapy given alone or combined with therapy directed at the skin.
Sources: therapy
Topical chemotherapy.
Sources: Topical chemotherapy
Systemic chemotherapy with one or more drugs, which may be combined with therapy directed at the skin.
Sources: Systemic chemotherapy · drugs
Other drug therapy (topical corticosteroids, retinoid therapy, lenalidomide, histone deacetylase inhibitors).
Sources: topical · corticosteroids · retinoid · lenalidomide · histone deacetylase inhibitors
Targeted therapy (brentuximab vedotin).
Sources: Targeted therapy · brentuximab vedotin
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed stage III and stage IV mycosis fungoides including Sézary syndrome is palliative (to relieve symptoms and improve the quality of life) and may include the following:
Sources: stage III · stage IV · palliative · symptoms · quality of life
Psoralen and ultraviolet A (PUVA) radiation therapy.
Sources: Psoralen and ultraviolet A (PUVA) radiation therapy
Ultraviolet B radiation therapy.
Sources: Ultraviolet B radiation · therapy
Extracorporeal photopheresis (ECP) given alone or combined with total skin electron beam radiation therapy.
Sources: Extracorporeal photopheresis · total skin electron beam radiation therapy
Radiation therapy with total skin electron beam radiation therapy. In some cases, radiation therapy is given to skin lesions, as palliative therapy to reduce tumor size to relieve symptoms and improve quality of life.
Sources: Radiation therapy · lesions · palliative therapy · tumor · symptoms · quality of life
Immunotherapy given alone or combined with therapy directed at the skin.
Sources: therapy
Systemic chemotherapy with one or more drugs, which may be combined with therapy directed at the skin.
Sources: Systemic chemotherapy · drugs
Topical chemotherapy.
Sources: Topical chemotherapy
Other drug therapy (topical corticosteroids, lenalidomide, bexarotene, histone deacetylase inhibitors).
Sources: topical · corticosteroids · lenalidomide · bexarotene · histone deacetylase inhibitors
Targeted therapy with brentuximab vedotin.
Sources: Targeted therapy · brentuximab vedotin
A clinical trial of immune checkpoint inhibitor therapy with pembrolizumab.
Sources: clinical trial · immune checkpoint inhibitor · pembrolizumab
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of recurrent mycosis fungoides including Sézary syndrome may be within a clinical trial and may include the following:
Sources: recurrent · mycosis fungoides · Sézary syndrome
Radiation therapy with total skin electron beam radiation therapy. In some cases, radiation therapy is given to skin lesions as palliative therapy to reduce tumor size to relieve symptoms and improve quality of life.
Sources: Radiation therapy · total skin electron beam radiation therapy · lesions · palliative therapy · tumor · symptoms · quality of life
Psoralen and ultraviolet A (PUVA) radiation therapy, which may be given with immunotherapy.
Sources: Psoralen and ultraviolet A (PUVA) radiation therapy
Ultraviolet B radiation.
Sources: Ultraviolet B radiation
Extracorporeal photopheresis (ECP).
Sources: Extracorporeal photopheresis
Systemic chemotherapy with one or more drugs.
Sources: Systemic chemotherapy · drugs
Other drug therapy (topical corticosteroids, retinoid therapy, lenalidomide, histone deacetylase inhibitors).
Sources: therapy · topical · corticosteroids · retinoid · lenalidomide · histone deacetylase inhibitors
Immunotherapy given alone or combined with therapy directed at the skin.
High-dose chemotherapy, and sometimes radiation therapy, with stem cell transplant.
Sources: High-dose chemotherapy · stem cell transplant
Targeted therapy (brentuximab vedotin or mogamulizumab).
Sources: Targeted therapy · brentuximab vedotin · mogamulizumab
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
The prognosis and treatment options depend on the following:
Sources: prognosis
The stage of the cancer.
Sources: stage
The type of lesion (patches, plaques, or tumors).
The patient's age and sex.
Mycosis fungoides and Sézary syndrome are hard to cure. Treatment is usually palliative, to relieve symptoms and improve the quality of life. Patients with earlystage disease may live many years.
Sources: cure · palliative · quality of life
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Mycosis fungoides and Sézary syndrome may come back in the skin or in other parts of the body, such as the spleen or liver.
Sources: Sézary syndrome · spleen
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
There are different types of treatment for patients with mycosis fungoides and cancer.
Seven types of standard treatment are used:
Seven types of standard treatment are used:
Photodynamic therapy
Radiation therapy
Chemotherapy
Other drug therapy
Immunotherapy
Targeted therapy
High-dose chemotherapy and radiation therapy with stem cell transplant
New types of treatment are being tested in clinical trials.
New types of treatment are being tested in clinical trials.
Immune checkpoint inhibitor therapy
Treatment for mycosis fungoides and Sézary syndrome may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up tests may be needed.
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Different types of treatment are available for patients with mycosis fungoides and . Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: mycosis fungoides · standard · clinical trials · research study · cancer
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Photodynamic therapy is a cancer treatment that uses a drug and a certain type of laser light to kill cancer cells. A drug that is not active until it is exposed to light is injected into a vein. The drug collects more in cancer cells than in normal cells. For skin cancer, laser light is shined onto the skin and the drug becomes active and kills the cancer cells. Photodynamic therapy causes little damage to healthy tissue. Patients undergoing photodynamic therapy will need to limit the amount of time spent in sunlight. There are different types of photodynamic therapy:
Sources: Photodynamic therapy · drug · laser · cells · injected · vein · skin cancer · tissue
In psoralen and ultraviolet A (PUVA) therapy, the patient receives a drug called psoralen and then ultraviolet A radiation is directed to the skin.
Sources: psoralen and ultraviolet A (PUVA) therapy · psoralen · ultraviolet A radiation
In extracorporeal photopheresis (ECP), the patient is given drugs and then some blood cells are taken from the body, put under a special ultraviolet A light, and put back into the body. ECP may be used alone or combined with total skin electron beam (TSEB) radiation therapy.
Sources: extracorporeal photopheresis · blood · ultraviolet A light · total skin electron beam (TSEB) radiation therapy
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Sometimes, total skin electron beam (TSEB) radiation therapy is used to treat mycosis fungoides and Sézary syndrome. This is a type of external radiation treatment in which a radiation therapy machine aims electrons (tiny, invisible particles) at the skin covering the whole body . External radiation therapy may also be used as palliative therapy to relieve symptoms and improve quality of life.
Sources: Radiation therapy · x-rays · radiation · External radiation therapy · electrons · palliative therapy · symptoms · quality of life
Ultraviolet A (UVA) radiation therapy or ultraviolet B (UVB) radiation therapy may be given using a special lamp or laser that directs radiation at the skin.
Sources: Ultraviolet A (UVA) radiation therapy · ultraviolet B (UVB) radiation therapy
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). Sometimes the chemotherapy is topical (put on the skin in a cream, lotion, or ointment).
Sources: Chemotherapy · systemic chemotherapy · ointment
See Drugs Approved for Non-Hodgkin Lymphoma for more information. (Mycosis fungoides and Sézary syndrome are types of non-Hodgkin lymphoma.)
Sources: Drugs Approved for Non-Hodgkin Lymphoma · non-Hodgkin lymphoma
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Topical corticosteroids are used to relieve red, swollen, and inflamed skin. They are a type of steroid. Topical corticosteroids may be in a cream, lotion, or ointment.
Sources: corticosteroids · inflamed · steroid
Retinoids, such as bexarotene, are drugs related to vitamin A that can slow the growth of certain types of cancer cells. The retinoids may be taken by mouth or put on the skin.
Sources: Retinoids · bexarotene · vitamin A
Lenalidomide is a drug that helps the immune system kill abnormal blood cells or cancer cells and may prevent the growth of new blood vessels that tumors need to grow.
Sources: Lenalidomide · immune system · abnormal · blood vessels
Vorinostat and romidepsin are two of the histone deacetylase (HDAC) inhibitors used to treat mycosis fungoides and Sézary syndrome. HDAC inhibitors cause a chemical change that stops tumor cells from dividing.
Sources: Vorinostat · romidepsin · histone deacetylase (HDAC) inhibitors
See Drugs Approved for Non-Hodgkin Lymphoma for more information. (Mycosis fungoides and Sézary syndrome are types of non-Hodgkin lymphoma.)
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer. This cancer treatment is a type of biologic therapy.
Sources: Immunotherapy · immune system · biologic therapy
Interferon: This treatment interferes with the division of mycosis fungoides and Sézary cells and can slow tumor growth.
Sources: Interferon · tumor
See Drugs Approved for Non-Hodgkin Lymphoma for more information. (Mycosis fungoides and Sézary syndrome are types of non-Hodgkin lymphoma.)
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do.
Sources: Targeted therapy
Monoclonal antibodies: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.Types of monoclonal antibodies include:
Sources: Monoclonal antibodies · proteins · antibodies · infusion · toxins · radioactive
Monoclonal antibodies: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.Types of monoclonal antibodies include:
Brentuximab vedotin, which contains a monoclonal antibody that binds to a protein, called CD30, found on some types of lymphoma cells. It also contains an anticancer drug that may help kill cancer cells.
Sources: Brentuximab vedotin · monoclonal antibody
Mogamulizumab, which contains a monoclonal antibody that binds to a protein, called CCR4, found on some types of lymphoma cells. It may block this protein and help the immune system kill cancer cells. It is used to treat mycosis fungoides and Sézary syndrome that came back or did not get better after treatment with at least one systemic therapy.
Sources: Mogamulizumab · protein · lymphoma · systemic therapy
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
High doses of chemotherapy and sometimes radiation therapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy and radiation therapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
Sources: doses · Stem cell transplant · Stem cells · bone marrow · donor · infusion
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Immune checkpoint inhibitor therapy: Immune checkpoint inhibitors block proteins called checkpoints that are made by some types of immune system cells, such as T cells, and some cancer cells. These checkpoints help keep immune responses from being too strong and sometimes can keep T cells from killing cancer cells. When these checkpoints are blocked, T cells can kill cancer cells better.
Sources: Immune checkpoint inhibitor · therapy · proteins · T cells · immune responses
PD-1 and PD-L1 inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body’s immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells. Pembrolizumab is a type of PD-1 inhibitor.
Sources: PD-1 · PD-L1 · Pembrolizumab
Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed stage I and stage II mycosis fungoides may include the following:
Psoralen and ultraviolet A (PUVA) radiation therapy.
Sources: Psoralen and ultraviolet A (PUVA) radiation therapy
Ultraviolet B radiation therapy.
Sources: Ultraviolet B radiation · therapy
Radiation therapy with total skin electron beam radiation therapy. In some cases, radiation therapy is given to skin lesions, as palliative therapy to reduce tumor size to relieve symptoms and improve quality of life.
Sources: Radiation therapy · total skin electron beam radiation therapy · lesions · palliative therapy · tumor · symptoms · quality of life
Immunotherapy given alone or combined with therapy directed at the skin.
Sources: therapy
Topical chemotherapy.
Sources: Topical chemotherapy
Systemic chemotherapy with one or more drugs, which may be combined with therapy directed at the skin.
Sources: Systemic chemotherapy · drugs
Other drug therapy (topical corticosteroids, retinoid therapy, lenalidomide, histone deacetylase inhibitors).
Sources: topical · corticosteroids · retinoid · lenalidomide · histone deacetylase inhibitors
Targeted therapy (brentuximab vedotin).
Sources: Targeted therapy · brentuximab vedotin
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed stage III and stage IV mycosis fungoides including Sézary syndrome is palliative (to relieve symptoms and improve the quality of life) and may include the following:
Sources: stage III · stage IV · palliative · symptoms · quality of life
Psoralen and ultraviolet A (PUVA) radiation therapy.
Sources: Psoralen and ultraviolet A (PUVA) radiation therapy
Ultraviolet B radiation therapy.
Sources: Ultraviolet B radiation · therapy
Extracorporeal photopheresis (ECP) given alone or combined with total skin electron beam radiation therapy.
Sources: Extracorporeal photopheresis · total skin electron beam radiation therapy
Radiation therapy with total skin electron beam radiation therapy. In some cases, radiation therapy is given to skin lesions, as palliative therapy to reduce tumor size to relieve symptoms and improve quality of life.
Sources: Radiation therapy · lesions · palliative therapy · tumor · symptoms · quality of life
Immunotherapy given alone or combined with therapy directed at the skin.
Sources: therapy
Systemic chemotherapy with one or more drugs, which may be combined with therapy directed at the skin.
Sources: Systemic chemotherapy · drugs
Topical chemotherapy.
Sources: Topical chemotherapy
Other drug therapy (topical corticosteroids, lenalidomide, bexarotene, histone deacetylase inhibitors).
Sources: topical · corticosteroids · lenalidomide · bexarotene · histone deacetylase inhibitors
Targeted therapy with brentuximab vedotin.
Sources: Targeted therapy · brentuximab vedotin
A clinical trial of immune checkpoint inhibitor therapy with pembrolizumab.
Sources: clinical trial · immune checkpoint inhibitor · pembrolizumab
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of recurrent mycosis fungoides including Sézary syndrome may be within a clinical trial and may include the following:
Sources: recurrent · mycosis fungoides · Sézary syndrome
Radiation therapy with total skin electron beam radiation therapy. In some cases, radiation therapy is given to skin lesions as palliative therapy to reduce tumor size to relieve symptoms and improve quality of life.
Sources: Radiation therapy · total skin electron beam radiation therapy · lesions · palliative therapy · tumor · symptoms · quality of life
Psoralen and ultraviolet A (PUVA) radiation therapy, which may be given with immunotherapy.
Sources: Psoralen and ultraviolet A (PUVA) radiation therapy
Ultraviolet B radiation.
Sources: Ultraviolet B radiation
Extracorporeal photopheresis (ECP).
Sources: Extracorporeal photopheresis
Systemic chemotherapy with one or more drugs.
Sources: Systemic chemotherapy · drugs
Other drug therapy (topical corticosteroids, retinoid therapy, lenalidomide, histone deacetylase inhibitors).
Sources: therapy · topical · corticosteroids · retinoid · lenalidomide · histone deacetylase inhibitors
Immunotherapy given alone or combined with therapy directed at the skin.
High-dose chemotherapy, and sometimes radiation therapy, with stem cell transplant.
Sources: High-dose chemotherapy · stem cell transplant
Targeted therapy (brentuximab vedotin or mogamulizumab).
Sources: Targeted therapy · brentuximab vedotin · mogamulizumab
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma
ClinicalTrials.gov recordCutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides
ClinicalTrials.gov recordCutaneous T-cell Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordCutaneous T-Cell Lymphoma
ClinicalTrials.gov recordPrimary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma
ClinicalTrials.gov recordPersistent or Recurrent Cutaneous T-Cell Lymphoma
ClinicalTrials.gov recordMycosis Fungoides, Sezary Syndrome
ClinicalTrials.gov recordCutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma, Disorder Related to Bone Marrow Transplantation
ClinicalTrials.gov recordPeripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma,...
ClinicalTrials.gov recordPeripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
ClinicalTrials.gov recordPeripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
ClinicalTrials.gov recordT-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T Cell Lymphoma (CTCL), T-Cell Prolymphocytic Leukemia
ClinicalTrials.gov recordRecurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides,...
ClinicalTrials.gov recordPeripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK T Cell Lymphoma, Extranodal NK T Cell Lymphoma, Nasal,...
ClinicalTrials.gov recordRelapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
ClinicalTrials.gov recordCutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
ClinicalTrials.gov record1.7 Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or CD30-Expressing Mycosis Fungoides (MF) ADCETRIS is indicated for the treatment of adult patients with pcALCL or CD30-expressing MF who have received prior...
Cutaneous T-Cell Lymphomas
1 INDICATIONS AND USAGE ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy.
ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy ( 1 ).
1 INDICATIONS AND USAGE LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Mycosis Fungoides
Persistent or recurrent cutaneous T-cell lymphoma expressing the CD25 component of IL-2 receptor
Treatment of Recurrent Mycosis Fungoides and Sézary Syndrome
Treatment of Recurrent Mycosis Fungoides and Sézary Syndrome
Treatment of Stage I and Stage II Mycosis Fungoides
Treatment of Stage I and Stage II Mycosis Fungoides
Treatment of Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome
Treatment of Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome
TARGRETIN (bexarotene) is a retinoid indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
1 INDICATIONS AND USAGE VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
VALCHLOR is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy ( 1 ).
1 INDICATIONS AND USAGE ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.
INDICATIONS AND USAGE When oral therapy is not feasible, the intramuscular use of CELESTONE ® SOLUSPAN ® Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, the intramuscular use of CELESTONE ® SOLUSPAN ® Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable...
DailyMed labelINDICATIONS AND USAGE A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the...
DailyMed labelINDICATIONS AND USAGE A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the...
DailyMed labelINDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the...
DailyMed labelINDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the...
DailyMed labelINDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the...
DailyMed labelINDICATIONS AND USAGE A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the...
DailyMed labelINDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the...
DailyMed labelINDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the...
DailyMed labelISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for the treatment of...
DailyMed labelLYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the...
DailyMed labelINDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in...
DailyMed labelINDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may...
DailyMed labelINDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may...
DailyMed labelINDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may...
DailyMed labelOrapred ODT (prednisolone sodium phosphate orally disintegrating tablet) is indicated in the treatment of the following diseases or conditions: Orapred ODT is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent...
DailyMed label1 INDICATIONS & USAGE Prednisolone sodium phosphate orally disintegrating tablets are indicated in the treatment of the following diseases or conditions: Prednisolone sodium phosphate orally disintegrating tablet is a corticosteroid...
DailyMed labelINDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of...
DailyMed labelINDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelIndications & Usage When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelIndications When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelINDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of...
DailyMed labelTARGRETIN ® (bexarotene) Capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. TARGRETIN (bexarotene) is a retinoid...
DailyMed labelVALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. VALCHLOR is an alkylating drug indicated for the topical...
DailyMed labelZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone...
DailyMed label